Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug level monitoring to optimize pharmacotherapy in heart failure
2023-506283-13-00Phase 4Authorised
- Sponsor
- University Hospital Ostrava
- Start
- Nov 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nebivolol, carvedilol, bisoprolol, spironolactone, sacubitril + valsartan and 1 more in heart failure with reduced ejection fraction (HFrEF), sponsored by University Hospital Ostrava. Planned start Nov 2023; status: authorised.
02
Drugs
nebivololcarvedilolbisoprololspironolactonesacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2023-506283-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506283-13-00.